Publications en collaboration avec des chercheurs de Complejo Asistencial Universitario de León (11)

2024

  1. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

  2. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

    Blood, Vol. 127, Núm. 24, pp. 3035-3039

2015

  1. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

    Leukemia

  2. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma

    Blood, Vol. 124, Núm. 8, pp. 1300-1303

  2. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2013

  1. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

    Haematologica, Vol. 98, Núm. 1, pp. 79-86

2011

  1. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

    Leukemia, Vol. 25, Núm. 4, pp. 697-706

  2. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2009

  1. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

    Blood, Vol. 114, Núm. 20, pp. 4369-4372